title: Prognostic value of ki-67 in breast carcinoma: tissue microarray method versus whole section analysis- potentials and pitfalls.
abstract: In our study we have compared the prognostic value of two distinct methods of immunohistochemical Ki-67 determination, tissue microarray (TMA) and classical whole section analysis. "Cut-off" values were used according to the 2009 St. Gallen Consensus. Tissue specimens were obtained from a consecutive retrospective series of 215 female patients with primary invasive tumours. Two hundred and thirteen patients were included in the study. Data on Ki-67 was collected by both tissue microarray (TMA) and whole section analysis. Follow up data on overall (OS) and disease-free survival (DFS) were collected. Median follow-up was 95 months (range from 7.8 through 107 months). Mutual correlation of two Ki-67 determination methods was non-significant (Person's r = 0.13417; p = 0.0528). There was statistically significant association of whole section Ki-67 expression with histological and nuclear grade, progesterone receptor and HER2/neu status. The expression of Ki-67 protein in TMAs correlated only with histological and nuclear grade, but not with other traditional clinicopathological factors. Statistically significant differences in DFS (p = 0.0156) and OS (p = 0.0028) were confirmed between subgroups with low and high whole section Ki-67 expression. When subgroups with high and intermediate expression were compared, significant difference was found in DFS (p = 0.0272), but not in OS (p = 0.0624). On the other hand, there was no statistically significant difference either in DFS, or in OS, according to the expression of Ki-67 in TMAs (p = 0.6529; p = 0.7883; p = 0.7966 for DFS, and p = 0.8917; p = 0.6448; p = 0.4323 for OS, respectively). In our study, classical whole section was superior to TMA analysis in terms of prognosis and clinicopathological correlation. Our results indicate that the method used may have impact on prognostic significance of Ki-67. Further studies are needed, covering a greater number of patients and including a precisely defined stage and treatment patient cohorts, in order to solve controversies in Ki-67 assessment methodology.
authors.affiliation: Department of Medical Oncology, Division of Oncology, University Hospital Centre, Zagreb, Croatia and University of Zagreb School of Medicine, Kišpatićeva 12, 10 000, Zagreb, Croatia, natalija.dedic-plavetic@zg.t-com.hr.
authors.forename: Natalija
authors.initials: N
authors.lastname: Dedić Plavetić
authors.forename: Jasminka
authors.initials: J
authors.lastname: Jakić-Razumović
authors.forename: Ana
authors.initials: A
authors.lastname: Kulić
authors.forename: Maja
authors.initials: M
authors.lastname: Sirotković-Skerlev
authors.forename: Marina
authors.initials: M
authors.lastname: Barić
authors.forename: Damir
authors.initials: D
authors.lastname: Vrbanec
mesh_terms: D014408:Biomarkers, Tumor / Q000235:genetics / Q000378:metabolism*; D001943:Breast Neoplasms / Q000175:diagnosis* / Q000378:metabolism / Q000401:mortality*; D049109:Cell Proliferation; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007150:Immunohistochemistry / Q000379:methods*; D019394:Ki-67 Antigen / Q000235:genetics / Q000378:metabolism*; D008875:Middle Aged; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate; D046888:Tissue Array Analysis / Q000379:methods*
chemical_list: D014408:Biomarkers, Tumor; D019394:Ki-67 Antigen
references.citation: J Natl Cancer Inst. 2008 Feb 6;100(3):207-12
references.pmid: 18230798
references.citation: Br J Cancer. 2012 Jan 17;106(2):383-8
references.pmid: 22251968
references.citation: J Clin Oncol. 2011 Nov 10;29(32):4273-8
references.pmid: 21990413
references.citation: Cancer J. 2001 Jan-Feb;7(1):24-31
references.pmid: 11269645
references.citation: J Pathol. 1999 Jan;187(2):207-16
references.pmid: 10365096
references.citation: Breast Cancer. 2015 Jan;22(1):71-8
references.pmid: 23479208
references.citation: J Clin Oncol. 2008 Dec 1;26(34):5569-75
references.pmid: 18981464
references.citation: Int J Cancer. 2006 May 1;118(9):2190-4
references.pmid: 16331604
references.citation: Breast. 2008 Aug;17(4):323-34
references.pmid: 18455396
references.citation: Anticancer Res. 1995 Nov-Dec;15(6B):2717-22
references.pmid: 8669852
references.citation: Cell Prolif. 2007 Jun;40(3):422-30
references.pmid: 17531085
references.citation: Cancer. 2002 Apr 15;94(8):2151-9
references.pmid: 12001111
references.citation: Breast Cancer Res. 2005;7(4):R465-9
references.pmid: 15987451
references.citation: Mod Pathol. 2005 Mar;18(3):374-81
references.pmid: 15578079
references.citation: J Pathol. 1992 Dec;168(4):357-63
references.pmid: 1484317
references.citation: Clin Cancer Res. 2008 Dec 15;14(24):8019-26
references.pmid: 19088018
references.citation: N Engl J Med. 2012 Mar 8;366(10):883-892
references.pmid: 22397650
references.citation: J Natl Cancer Inst. 2011 Nov 16;103(22):1656-64
references.pmid: 21960707
references.citation: Ann Oncol. 2005 Nov;16(11):1723-39
references.pmid: 15980158
references.citation: BMC Cancer. 2008 Oct 06;8:287
references.pmid: 18837981
references.citation: J Clin Oncol. 2005 Oct 1;23(28):7212-20
references.pmid: 16192605
references.citation: J Clin Oncol. 1987 Sep;5(9):1378-86
references.pmid: 3625256
references.citation: J Natl Cancer Inst. 2009 May 20;101(10):736-50
references.pmid: 19436038
references.citation: Breast Cancer Res Treat. 2010 Jan;119(2):315-23
references.pmid: 19247830
references.citation: J Natl Cancer Inst. 2007 Jan 17;99(2):167-70
references.pmid: 17228000
references.citation: Cancer. 1991 Jan 15;67(2):421-8
references.pmid: 1845945
references.citation: Br J Cancer. 2007 May 21;96(10):1504-13
references.pmid: 17453008
references.citation: Cancer. 2003 Mar 1;97(5):1321-31
references.pmid: 12599241
references.citation: Breast Cancer Res Treat. 2007 Mar;102(1):61-73
references.pmid: 16850244
references.citation: Cytometry. 1991;12(1):42-9
references.pmid: 1999122
references.citation: Histopathology. 1991 Nov;19(5):403-10
references.pmid: 1757079
references.citation: Histopathology. 2002 Jan;40(1):2-11
references.pmid: 11903593
references.citation: Lancet Oncol. 2010 Feb;11(2):174-83
references.pmid: 20152769
references.citation: J Cell Physiol. 2006 Mar;206(3):624-35
references.pmid: 16206250
references.citation: J Clin Oncol. 2009 Jun 10;27(17):2809-15
references.pmid: 19380452
references.citation: Diagn Pathol. 2011 Mar 30;6 Suppl 1:S7
references.pmid: 21489202
references.citation: Int J Cancer. 1983 Jan 15;31(1):13-20
references.pmid: 6339421
references.citation: Eur J Surg Oncol. 2008 Dec;34(12):1299-303
references.pmid: 18164172
references.citation: J Cell Physiol. 2000 Mar;182(3):311-22
references.pmid: 10653597
references.citation: Ann Oncol. 2009 Aug;20(8):1319-29
references.pmid: 19535820
references.citation: Oncology. 2013;84(3):135-40
references.pmid: 23235554
references.citation: Breast. 2009 Apr;18(2):135-41
references.pmid: 19342238
references.citation: Am J Pathol. 1999 Dec;155(6):1811-5
references.pmid: 10595909
references.citation: Cancer. 1991 Jan 1;67(1):106-15
references.pmid: 1985705